2022/05/12 ALA-1000 Received notice of patent allowance from European Patent Office (EPO) , Application No. 17850245.6 Post author:alarpharm Post published:13 . 5 . 2022 Post category:Media releases You Might Also Like 2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021 2021/11/30 ALA-1000 Received notice of patent allowance from Directorate General of Intellectual Property (DGIP) of Indonesia, Application No. P00201902139.. 17 . 12 . 2021 2022/12/05 ALA-1000 received notice of patent allowance from Companies and Intellectual Property Commission of Republic of South Africa , Application No. 2020/04582 6 . 12 . 2022 2023/07/19 ALA-1300 Received the patent, LONG-ACTING INJECTABLE FORMULATIONS AND CRYSTALLINE FORMS OF BUPRENORPHINE DERIVATIVES , from Directorate General of Intellectual Property Rights (DGIP) of Indonesia, NO IDP 000 087828 B 26 . 7 . 2023 2023/08/07 ALA-3000 has received an Resolution of acceptance to registration from Instituto Nacional de Propiedad Industrial (INAPI)-Chile after the examination. (Patent Application No. 202101803) 10 . 8 . 2023
2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021
2021/11/30 ALA-1000 Received notice of patent allowance from Directorate General of Intellectual Property (DGIP) of Indonesia, Application No. P00201902139.. 17 . 12 . 2021
2022/12/05 ALA-1000 received notice of patent allowance from Companies and Intellectual Property Commission of Republic of South Africa , Application No. 2020/04582 6 . 12 . 2022
2023/07/19 ALA-1300 Received the patent, LONG-ACTING INJECTABLE FORMULATIONS AND CRYSTALLINE FORMS OF BUPRENORPHINE DERIVATIVES , from Directorate General of Intellectual Property Rights (DGIP) of Indonesia, NO IDP 000 087828 B 26 . 7 . 2023
2023/08/07 ALA-3000 has received an Resolution of acceptance to registration from Instituto Nacional de Propiedad Industrial (INAPI)-Chile after the examination. (Patent Application No. 202101803) 10 . 8 . 2023
